Two new appointments at Eastbound Shanghai Institute
This article was originally published in Scrip
Executive Summary
Eastbound Shanghai Institute, a subsidiary of Eastbound Synopharma (China), has appointed Dr Young Lo as research fellow, effective November 16th, and Chris Vance as vice-president for sales, marketing and business development. Dr Lo has more than 35 years' experience in chemical process development in the pharmaceutical industry, having previously worked at A H Robins, DuPont Merck and Boehringer Ingelheim. Mr Vance has more than 30 years of experience in the chemical and pharmaceutical industry, having formerly served as head of the sales and marketing team at Boehringer Ingelheim Chemicals.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.